Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Exclusion Criteria

• •1. Febrile illness in the previous 3 days
• •2. Prior vaccination with a measles, mumps, rubella and/or varicella vaccine either alone or in any combination
• •3. Exposure to measles, mumps, rubella, varicella and/or zoster in the previous 30 days
• •4. Tuberculin test done in the previous 2 days
• •5. Severe chronic disease
• •6. Known active tuberculosis
• •7. Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition
• •8. Hereditary problems of fructose intolerance
• •9. Prior known sensitivity or allergy to any component of the vaccine
• •10. Known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems
• •11. Humoral or cellular immunodeficiency,
• •12. Immunosuppressive therapy \[including systemic corticosteroids (a), given daily or on alternate days at high doses (\>=2 mg/kg/day prednisone equivalent or \>=20 mg/day if the subject's weight was \>10 kg) during at least 14 days in the previous 30 days\]
• •13. Family history of congenital or hereditary immunodeficiency
• •14. Receipt of immunoglobulins or blood-derived products in the previous 150 days or scheduled to be administered through Visit 5
• •15. Receipt of an inactivated vaccine in the previous 14 days
• •16. Receipt of a live non-study vaccine in the previous 28 days
• •17. Any medical condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objectives
• •18. Current participation or scheduled participation in any other clinical study through Visit 5